In Brief This Week: GenDx, KimerDx; Mo Bio Laboratories; Arca biopharma, LabCorp; Perthera | GenomeWeb

NEW YORK (GenomeWeb News) – Genome Diagnostics (GenDx) announced this week the launch of KimerDx, a spinout of GenDx focused on developing solid organ transplant tests for monitoring disease relapse and transplant rejection. The new firm is led by Doug Bost as managing director. He previously served as director of reagent development and instrument systems at Quest Diagnostics' Celera business.

Utrecht, Netherlands-based KimerDx also announced that it had won €25,000 ($34,200) from the Netherlands Genomics Initiative's Venture Challenge Fall 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.